Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the ...

PHOENIX — The oral medication resmetirom significantly improved liver stiffness and reduced portal hypertension in metabolic ...

Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL ...

The New York Mets' infield depth is being tested already, and it's only their second day of spring training games. On Sunday, in a split-squad game against the Washington Nationals, utility infielder ...

Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.

Nick Madrigal dislocated his left shoulder during today’s Spring Training split-squad game between the Mets and Nationals. In the first inning of the game, Madrigal (who was playing shortstop) had to ...

Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable ...

With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) future prospects. Madrigal Pharmaceuticals, Inc., a ...

Madrigal Pharmaceuticals broke new ground earlier this year as its Rezdiffra became the first drug approved by the FDA to treat metabolic dysfunction-associated steatohepatitis (MASH). Now, with its ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...